Key Takeaways AVTR shows growth potential with a broad product portfolio and strategic deals, despite Lab Solutions' lag.AVTR logged about $100M in new pharma wins and extended key contracts, boosting revenue visibility.AVTR is advancing a cost transformation, targeting $400M run-rate savings by 2027.Avantor, Inc. (AVTR) is well-poised for growth in the coming quarters, courtesy of its strong product portfolio. The optimism led by strategic deals and cost transformation progress also looks promising. Howeve ...